Integrilin 0,75mg/ml solution for infusion

Pajjiż: Armenja

Lingwa: Ingliż

Sors: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Ingredjent attiv:

eptifibatide

Disponibbli minn:

Glaxo Operations UK Ltd.

Kodiċi ATC:

B01AC16

INN (Isem Internazzjonali):

eptifibatide

Dożaġġ:

0,75mg/ml

Għamla farmaċewtika:

solution for infusion

Unitajiet fil-pakkett:

glass vial 100ml

Tip ta 'preskrizzjoni:

Prescription

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2019-09-23

Fuljett ta 'informazzjoni

62000000028657
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
−
Keep this leaflet. You may need to read it again.
−
If you have any further questions, ask your doctor or hospital
pharmacist or nurse.
−
If you get any side effects talk to your doctor or hospital pharmacist
or nurse. This includes any
possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Integrilin is and what it is used for
2.
What you need to know before you are given Integrilin
3.
How to use Integrilin
4.
Possible side effects
5.
How to store Integrilin
6.
Contents of the pack and other information
1.
WHAT INTEGRILIN IS AND WHAT IT IS USED FOR
Integrilin is an inhibitor of platelet aggregation. This means that it
helps to prevent blood clots from
forming.
It is used in adults with manifestation of severe coronary
insufficiency defined as spontaneous and recent
chest pain with electrocardiographic abnormalities or biological
changes. It is usually given with aspirin
and unfractionated heparin.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN INTEGRILIN
YOU MUST NOT BE GIVEN INTEGRILIN:
−
if you are allergic to eptifibatide or any of the other ingredients of
this medicine (listed in section 6).
−
if you have recently had bleeding from your stomach, intestines,
bladder or other organs, for example
if you have seen abnormal blood in your stool or urine (except from
menstrual bleeding) in the past
30 days.
−
if you have had a stroke within the past 30 days or any haemorrhagic
stroke (also, be sure your doctor
knows if you ever had a stroke).
−
if you have had a brain tumour or a condition that affects the blood
vessels around the brain.
−
if you had a major operation or severe injury during the past 6 weeks.
−
if you have or have had bleeding problems.
−
if you have or have had difficulty with your blood clotting or a low
blood platelet count.
−
if you have or have had

Karatteristiċi tal-prodott

SUMMARY OF PRODUCT CHARACTERISTICS
Integrilin 0.75 mg/ml solution for infusion
1. NAME OF THE MEDICINAL PRODUCT
INTEGRILIN 0.75 mg/ml solution for infusion
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of solution for infusion contains 0.75 mg of eptifibatide.
One vial of 100 ml of solution for infusion contains 75 mg of
eptifibatide. For the full list of
excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Solution for infusion.
Clear, colourless solution.
4. CLINICAL PARTICULARS
4.1. THERAPEUTIC INDICATIONS
INTEGRILIN is intended for use with acetylsalicylic acid and
unfractionated heparin.
INTEGRILIN is indicated for the prevention of early myocardial
infarction in adults presenting
with unstable angina or non-Q-wave myocardial infarction, with the
last episode of chest pain
occurring within 24 hours and with electrocardiogram (ECG) changes
and/or elevated cardiac
enzymes.
Patients most likely to benefit from INTEGRILIN treatment are those at
high risk of developing
myocardial infarction within the first 3-4 days after onset of acute
angina symptoms including for
instance those that are likely to undergo an early PTCA (Percutaneous
Transluminal Coronary
Angioplasty) (see section 5.1).
4.2. POSOLOGY AND METHOD OF ADMINISTRATION
This product is for hospital use only. It should be administered by
specialist physicians
experienced in the management of acute coronary syndromes.
INTEGRILIN solution for infusion must be used in conjunction with
INTEGRILIN solution for
injection.
Concurrent administration of heparin is recommended unless this is
contraindicated for reasons
such as a history of thrombocytopenia associated with use of heparin
(see ‘Heparin
administration’, section 4.4). INTEGRILIN is also intended for
concurrent use with acetylsalicylic
acid, as it is part of standard management of patients with acute
coronary syndromes, unless
its use is contraindicated.
Posology
_Adults (_≥_18 years of age) presenting with unstable angina (UA) or
non-Q-wave myocardial _
_infarction (NQMI) _
_ _
The recommen